Description

Etravirine-d8 is the deuterium labeled Etravirine. Etravirine (R165335) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used for the treatment of HIV[1][2].–Applications-COVID-19-anti-virus-Formula-C20H9D6BrN6O-Citation–References-[1]Andries, K., et al. TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother, 2004. 48(12): p. 468|[2]Lazzarin, A., et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet, 2007. 370(9581): p. 39-48.|[3]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.-CASNumber-1142096-06-7-MolecularWeight-443.33-Compound Purity–SMILES-O(C1=NC(NC2=CC=C(C#N)C=C2)=NC(N)=C1Br)C3=C(C([2H])([2H])[2H])C=C(C#N)C=C3C([2H])([2H])[2H]-Research_Area-Infection-Solubility-10 mM in DMSO-Target-HIV;Isotope-Labeled Compounds;Reverse Transcriptase-Isoform–Pathway-Anti-infection;Others-MCE Product type-Isotope-Labeled Compounds